Fly News Breaks for February 26, 2020
Feb 26, 2020 | 07:14 EDT
H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on Iovance Biotherapeutics to $36 from $32 and keeps a Buy rating on the shares. The company's primary focus for 2020 remains both delivering pivotal data for melanoma and cervical cancer, and filing both Biologics License Applications by year-end, Pantginis tells investors in a post-earnings research note. The analyst also highlights the potential for a takeout of Iovance, which he says has been an underlying thesis of his for years and resurfaced in unconfirmed press reports again yesterday.
News For IOVA From the Last 2 Days
There are no results for your query IOVA